$1.54 Billion is the total value of Redmile Group, LLC's 60 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARRY | Sell | ARRAY BIOPHARMA INC | $114,127,000 | -21.9% | 12,765,862 | -23.2% | 7.41% | -41.2% |
| PEN | Sell | PENUMBRA INC | $86,321,000 | +30.1% | 1,034,408 | -0.6% | 5.60% | -2.1% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $81,110,000 | +32.3% | 11,375,852 | -7.7% | 5.26% | -0.4% |
| CLVS | Sell | CLOVIS ONCOLOGY INC | $61,932,000 | -14.0% | 972,696 | -40.0% | 4.02% | -35.2% |
| SGEN | Sell | SEATTLE GENETICS INC | $43,775,000 | -45.5% | 696,386 | -54.2% | 2.84% | -58.9% |
| INCY | Sell | INCYTE CORP | $41,133,000 | -9.2% | 307,723 | -31.9% | 2.67% | -31.7% |
| GWPH | Sell | GW PHARMACEUTICALS PLCads | $40,218,000 | -1.7% | 332,544 | -9.2% | 2.61% | -26.0% |
| Sell | NEURODERM LTD | $24,540,000 | -29.2% | 924,304 | -40.8% | 1.59% | -46.7% | |
| ESRX | Sell | EXPRESS SCRIPTS HLDG CO | $19,365,000 | -16.9% | 293,807 | -13.3% | 1.26% | -37.4% |
| NSTG | Sell | NANOSTRING TECHNOLOGIES INC | $18,567,000 | -11.2% | 934,424 | -0.4% | 1.20% | -33.2% |
| BOLD | Sell | AUDENTES THERAPEUTICS INC | $13,987,000 | -8.1% | 820,836 | -1.4% | 0.91% | -30.7% |
| CTMX | Sell | CYTOMX THERAPEUTICS INC | $11,776,000 | +53.7% | 681,892 | -2.2% | 0.76% | +15.8% |
| CRL | Sell | CHARLES RIV LABS INTL INC | $10,912,000 | -42.0% | 121,307 | -50.9% | 0.71% | -56.4% |
| NVTA | Sell | INVITAE CORP | $8,983,000 | +6.2% | 812,240 | -23.7% | 0.58% | -20.0% |
| PRQR | Sell | PROQR THRAPEUTICS N V | $7,766,000 | +0.4% | 1,553,225 | -1.6% | 0.50% | -24.4% |
| DVAX | Sell | DYNAVAX TECHNOLOGIES CORP | $6,066,000 | +46.3% | 1,019,491 | -2.9% | 0.39% | +10.4% |
| ACRS | Sell | ACLARIS THERAPEUTICS INC | $2,705,000 | +5.8% | 90,700 | -3.7% | 0.18% | -20.0% |
| RARX | Sell | RA PHARMACEUTICALS INC | $2,358,000 | -13.9% | 110,769 | -38.6% | 0.15% | -35.2% |
| IBB | Exit | ISHARES TRnasdq biotec etf | $0 | – | -4,500 | -100.0% | -0.10% | – |
| WOOF | Exit | VCA INC | $0 | – | -70,040 | -100.0% | -0.41% | – |
| IRTC | Exit | IRHYTHM TECHNOLOGIES INC | $0 | – | -228,800 | -100.0% | -0.59% | – |
| NVRO | Exit | NEVRO CORP | $0 | – | -260,380 | -100.0% | -1.63% | – |
| CNC | Exit | CENTENE CORP DEL | $0 | – | -516,598 | -100.0% | -2.52% | – |
| ARIA | Exit | ARIAD PHARMACEUTICALS INC | $0 | – | -3,838,376 | -100.0% | -4.12% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 43 | Q3 2023 | 10.1% |
| ATARA BIOTHERAPEUTICS INC | 36 | Q3 2023 | 6.4% |
| FATE THERAPEUTICS INC | 34 | Q3 2023 | 17.2% |
| INVITAE CORP | 32 | Q3 2023 | 2.7% |
| REGENXBIO INC | 28 | Q3 2023 | 3.8% |
| CLOVIS ONCOLOGY INC | 27 | Q1 2020 | 6.7% |
| IMMUNOGEN INC | 27 | Q3 2023 | 13.2% |
| CASTLIGHT HEALTH INC SAN FRAN COM STK | 27 | Q1 2021 | 2.5% |
| ARRAY BIOPHARMA INC | 26 | Q2 2019 | 12.6% |
| DECIPHERA PHARMACEUTICALS IN | 25 | Q3 2023 | 7.0% |
View Redmile Group, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | July 27, 2023 | 2,912,228 | 6.6% |
| IGM Biosciences, Inc. | June 28, 2023 | 3,291,092 | 9.9% |
| MedAvail Holdings, Inc. | June 21, 2023 | 124,507,268 | 73.1% |
| Achilles Therapeutics plc | February 14, 2023 | 1,608,089 | 3.9% |
| Kymera Therapeutics, Inc. | February 14, 2023 | 2,673,837 | 4.9% |
| Old Ayala, IncSold out | February 08, 2023 | 0 | 0.0% |
| Zymeworks Inc. | August 08, 2022 | 5,758,241 | 9.9% |
| Science 37 Holdings, Inc. | June 15, 2022 | 19,808,234 | 17.1% |
| Allakos Inc. | February 14, 2022 | 2,077,875 | 3.8% |
| Aprea Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Redmile Group, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-19 |
| 4 | 2024-03-14 |
| 4 | 2024-03-13 |
| SC 13D/A | 2024-03-13 |
| 4 | 2024-03-05 |
| SC 13D/A | 2024-03-05 |
View Redmile Group, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.